| 前收盘价格 | 11.41 |
| 收盘价格 | 11.49 |
| 成交量 | 475,854 |
| 平均成交量 (3个月) | 491,275 |
| 市值 | 530,546,560 |
| 价格/销量 (P/S) | 5.10 |
| 股市价格/股市净资产 (P/B) | 19.27 |
| 52周波幅 | |
| 利润日期 | 12 May 2025 |
| 营业毛利率 | -140.35% |
| 营业利益率 (TTM) | -108.11% |
| 稀释每股收益 (EPS TTM) | -2.96 |
| 季度收入增长率 (YOY) | 4.40% |
| 总债务/股东权益 (D/E MRQ) | 481.07% |
| 流动比率 (MRQ) | 6.01 |
| 营业现金流 (OCF TTM) | -96.77 M |
| 杠杆自由现金流 (LFCF TTM) | -46.83 M |
| 资产报酬率 (ROA TTM) | -25.78% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | UroGen Pharma Ltd. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 5.0 |
| 平均 | 2.38 |
|
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 8.40% |
| 机构持股比例 | 86.98% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 55.00 (HC Wainwright & Co., 377.85%) | 购买 |
| 中 | 25.00 (117.20%) | |
| 低 | 16.00 (Goldman Sachs, 39.01%) | 保留 |
| 平均值 | 30.00 (160.64%) | |
| 总计 | 4 购买, 1 保留 | |
| 平均价格@调整类型 | 10.68 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| D. Boral Capital | 28 Apr 2025 | 25.00 (117.20%) | 购买 | 11.26 |
| 13 Mar 2025 | 25.00 (117.20%) | 购买 | 10.90 | |
| HC Wainwright & Co. | 28 Apr 2025 | 55.00 (377.85%) | 购买 | 11.26 |
| 11 Mar 2025 | 55.00 (377.85%) | 购买 | 10.82 | |
| Goldman Sachs | 17 Apr 2025 | 16.00 (39.01%) | 保留 | 9.67 |
| Scotiabank | 16 Apr 2025 | 23.00 (99.83%) | 购买 | 10.39 |
| Ladenburg Thalmann | 19 Feb 2025 | 31.00 (169.33%) | 购买 | 10.82 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合